National Medical Products Administration: Currently, China's research and development pipeline for innovative drugs accounts for about 1/4 of the global total.

According to statistics from the National Medical Products Administration, China approved 43 new innovative drugs in the first half of the year, a year-on-year increase of 59%, approaching the full-year number of 48 innovative drugs approved in 2024. Yang Ting, director of the Drug Registration Management Department of the National Medical Products Administration, said that in terms of research and development pipelines, China currently accounts for about a quarter of the global pipeline of innovative drugs. In clinical trials, we have about 3,000 projects conducting clinical trials each year, which puts us at the forefront in the world. It is understood that the National Medical Products Administration will focus on increasing policy supply to guide and encourage companies to conduct innovative drug research and development based on clinical value. Yang Ting told reporters that the National Medical Products Administration will also improve drug evaluation and approval procedures and rules, improve research and development quality and efficiency, and encourage innovation in the development of multi-link vaccines, cellular and gene therapy products.